Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Urology

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1660146

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1660146

BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride)), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030

PUBLISHED:
PAGES: 329 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global BPH surgical treatment market is valued at an estimated 12.62 billion in 2024 and is projected to reach USD 17.19 billion by 2030, at a CAGR of 5.3% during the forecast period. The growing elderly male population is leading to the cause of BPH patients globally. Therefore, BPH is related to age, and aging is known as a risk factor for BPH. Approximately 50% of men over the age of 50 and around 80% of men over the age of 70 are under the influence of BPH.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD)
SegmentsBy Drug Type, By Type, Therapy, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East Africa

In 2023, the alpha-blockers segment accounted for the largest share of the BPH surgical treatment market, by drug type.

Alpha-blockers, 5-alpha reductase inhibitors, and other drug types make up the drug-type-based segments of the BPH surgical treatment market. Market share for BPH surgical treatment was highest in the Alpha-blockers in 2023. This is mainly due to the Alpha-blockers being recommended as first-line treatment for BPH. a-blockers relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction.

"The home care settings segment is projected to witness the highest growth rate in BPH surgical treatment market, by the end-user, during the forecast period."

Based on end users, the BPH surgical treatment market is segmented into hospitals, ambulatory surgery centers & clinics, and home care settings. The driving factors that force home care settings to BPH surgical treatment is that the patients prefer taking medicine over surgery in most cases, which has supported the growth of this segment. Also, patients avoid surgical or minimally invasive procedures (e.g., TURP, laser therapy) due to potential complications, discomfort, or recovery time.

"The Asia Pacific region is projected to witness highest growth rate in the BPH surgical treatment market during the forecast period"

The global BPH surgical treatment market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Throughout the forecast period, the BPH surgical treatment market is expected to grow at the fastest rate in the Asia Pacific region. The demand for BPH surgical treatment in the APAC is mainly driven by the growing geriatric population, the increasing GDP of Asian countries, the rising healthcare expenditure in the APAC countries, and growing public awareness.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 50%, Tier 2 - 30%, and Tier 3 - 20%
  • By Designation: C-level - 25%, D-level - 20%, and Others - 55%
  • By Region: North America - 35%, Europe - 32%, Asia Pacific - 21%, Latin America - 8%, Middle East & Africa - 1%, and the GCC Countries - 3%

Lists of Companies Profiled in the Report:

GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc.(Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark), IPG Photonics Corporation (Russia), ProstaLund AB (Sweden), Karl Storz Se & Co. KG (Germany), Richard Wolf Gmbh (Germany), and Quanta System (Italy), Asclepion Laser Technologies GmbH (Germany), Cook Medical (US), SRS Medical (US), Pnn Medical A/S (Denmark), Allium Ltd. (Israel), Urologix, LLC (US), and Medifocus, Inc. (Canada).

Research Coverage:

In this report, the BPH surgical treatment market has been categorized based on drug type (alpha-blockers, 5-alpha reductase inhibitors, and other drug types), type (Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezum Procedure, Robot-assisted waterjet ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic arterial embolization (PAE) and others) end user (hospitals, ASCs & clinics, and home care settings), therapy (monotherapy and combination drug therapy), and region (Europe, Middle East & Africa, North America, Latin America, Asia Pacific, and the GCC Countries).

Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the BPH surgical treatment market's expansion is included in detail in this study. An exhaustive study of the key players in the cochlear implants market has been done to provide insights into their business profiles, products offered, noteworthy strategies, product launches, and approvals, and other recent activities pertaining to the market.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall BPH surgical treatment market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restraints.

The report provides insights on the following pointers:

  • Analysis of key drivers: (Expanding aging population and increasing prevalence of BPH, Rising cases of obesity in males, and Growing preference for minimally invasive surgeries), restraints (High cost of cochlear implants and associated surgeries and surgical risks, procedural complications, and long post-surgery rehabilitation), opportunities (Side effects associated with BPH medications and High cost of BPH surgical treatment), and challenges (Shortage of skilled professionals, Low awareness regarding prostate health and Product recalls) influencing the growth of the in BPH surgical treatment market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the BPH surgical treatment market across varied regions.
  • Product Development/Innovation: Comprehensive information about product development and new technologies - the report analyses the BPH surgical treatment market.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the BPH surgical treatment market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc. (Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Limited (India), Teleflex Incorporated (US) and Boston Scientific Corporation (US), Olympus Corporation (Japan), Procept BioRobotics Corporation (US), Coloplast Group (Denmark) and IPG Photonics Corporation (Russia) in the BPH surgical treatment market strategies.
Show more
Product Code: MD 7836

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 LIMITATIONS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach, by type
      • 2.2.1.2 Approach 1: Company revenue estimation approach, by drug type
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.4 MARKET SHARE ANALYSIS
    • 2.4.1 STUDY ASSUMPTIONS
    • 2.4.2 GROWTH RATE ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS
    • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.5.2 SCOPE-RELATED LIMITATIONS
  • 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 BPH SURGICAL TREATMENT MARKET OVERVIEW
  • 4.2 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE AND COUNTRY (2024)
  • 4.3 BPH SURGICAL TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 BPH SURGICAL TREATMENT MARKET: REGIONAL MIX (2024-2030)

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Expanding aging population and increasing prevalence of benign prostatic hyperplasia
      • 5.2.1.2 Rising cases of obesity in males
      • 5.2.1.3 Growing preference for minimally invasive surgeries
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Side effects associated with BPH medications
      • 5.2.2.2 High cost of BPH surgical treatment
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth potential of emerging economies
      • 5.2.3.2 Favorable funding investments for BHP drug development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of skilled professionals
      • 5.2.4.2 Low awareness regarding prostate health
      • 5.2.4.3 Product recalls
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 SUPPLY CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 THREAT OF SUBSTITUTES
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 BARGAINING POWER OF SUPPLIERS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.7.2 BUYING CRITERIA
  • 5.8 REGULATORY SCENARIO
    • 5.8.1 PHARMACEUTICAL INDUSTRY
      • 5.8.1.1 Regulatory requirements
        • 5.8.1.1.1 EU regulations
        • 5.8.1.1.2 US regulations
    • 5.8.2 MEDICAL DEVICES INDUSTRY
      • 5.8.2.1 US
      • 5.8.2.2 Canada
      • 5.8.2.3 Europe
      • 5.8.2.4 Asia Pacific
        • 5.8.2.4.1 Japan
        • 5.8.2.4.2 China
        • 5.8.2.4.3 India
      • 5.8.2.5 Latin America
        • 5.8.2.5.1 Brazil
        • 5.8.2.5.2 Mexico
      • 5.8.2.6 Middle East
      • 5.8.2.7 Africa
    • 5.8.3 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE TREND FOR UROLIFT, BY REGION, 2021-2023
    • 5.9.2 AVERAGE SELLING PRICING TREND FOR AVODART, BY REGION, 2021-2023
    • 5.9.3 AVERAGE SELLING PRICING TREND FOR BPH SURGICAL TREATMENT PROCEDURES, 2021-2023
  • 5.10 TECHNOLOGY ANALYSIS
    • 5.10.1 KEY TECHNOLOGIES
      • 5.10.1.1 Minimally invasive surgical techniques
    • 5.10.2 COMPLEMENTARY TECHNOLOGIES
      • 5.10.2.1 Robotic & AI-assisted surgical systems
    • 5.10.3 ADJACENT TECHNOLOGIES
      • 5.10.3.1 MRI-ultrasound imaging
  • 5.11 PESTLE ANALYSIS
  • 5.12 PATENT ANALYSIS
  • 5.13 TRADE ANALYSIS
    • 5.13.1 TRADE ANALYSIS FOR ENDOSCOPES
    • 5.13.2 TRADE ANALYSIS FOR TADALAFIL
  • 5.14 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.16 IMPACT OF GENERATIVE AI/AI ON BPH SURGICAL TREATMENT MARKET
  • 5.17 INVESTMENT & FUNDING SCENARIO

6 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE

  • 6.1 INTRODUCTION
    • 6.1.1 ALPHA-BLOCKERS
      • 6.1.1.1 Tamsulosin
        • 6.1.1.1.1 Oldest prescribed drug with minimal effects on blood pressure to fuel uptake
      • 6.1.1.2 Silodosin
        • 6.1.1.2.1 Launch of generics to boost demand
      • 6.1.1.3 Alfuzosin
        • 6.1.1.3.1 Associated side effects to restrain market adoption
      • 6.1.1.4 Doxazosin
        • 6.1.1.4.1 Ability to provide long-term results to fuel uptake
      • 6.1.1.5 Other alpha-blockers
    • 6.1.2 5-ALPHA REDUCTASE INHIBITORS
      • 6.1.2.1 Dutasteride
        • 6.1.2.1.1 Slow but gradual reduction in symptoms to boost demand
      • 6.1.2.2 Finasteride
        • 6.1.2.2.1 Ability to decrease PSA levels to support market growth
    • 6.1.3 OTHER DRUG TYPES

7 BPH SURGICAL TREATMENT MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • 7.1.1 TRANSURETHRAL RESECTION OF THE PROSTATE (TURP)
      • 7.1.1.1 Gold standard for BPH treatment to boost demand
    • 7.1.2 LASER SURGERIES
      • 7.1.2.1 Evolution in lasers and high efficacy to boost demand
    • 7.1.3 UROLIFT PROCEDURES
      • 7.1.3.1 High safety and convenience to boost demand
    • 7.1.4 REZUM PROCEDURES
      • 7.1.4.1 Convenience of being conducted in outpatient settings to support market growth
    • 7.1.5 ROBOT-ASSISTED WATERJET ABLATION
      • 7.1.5.1 Advanced real-time capabilities with image-guided features to propel market
    • 7.1.6 PROSTATIC STENTS
      • 7.1.6.1 Temporarily designed for short-term use to support market growth
    • 7.1.7 TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT)
      • 7.1.7.1 Lower risk of bleeding without hospitalization to fuel market
    • 7.1.8 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE (TUNA)
      • 7.1.8.1 Favorable reimbursement policies to boost demand
    • 7.1.9 PROSTATIC ARTERIAL EMBOLIZATION (PAE)
      • 7.1.9.1 Minimally invasive technique to fuel uptake
    • 7.1.10 OTHER PROCEDURES

8 BPH SURGICAL TREATMENT MARKET, BY THERAPY

  • 8.1 INTRODUCTION
  • 8.2 MONOTHERAPY
    • 8.2.1 UTILIZATION OF SINGLE MEDICATION TO PROPEL MARKET
  • 8.3 COMBINATION DRUG THERAPY
    • 8.3.1 HIGH UTILIZATION FOR PATIENTS WITH RAPID PROGRESSION RATES TO DRIVE MARKET

9 BPH SURGICAL TREATMENT MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    • 9.2.1 HIGH PURCHASING POWER FOR ADVANCED BPH SURGICAL EQUIPMENT TO DRIVE MARKET
  • 9.3 AMBULATORY SURGERY CENTERS & CLINICS
    • 9.3.1 LOWER COST AND SHORTER PATIENT STAYS TO PROPEL MARKET
  • 9.4 HOME CARE SETTINGS
    • 9.4.1 CONVENIENCE AND COST-EFFICIENT BENEFITS TO FUEL MARKET

10 BPH SURGICAL TREATMENT MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Presence of key medical device manufacturers to boost demand
    • 10.2.3 CANADA
      • 10.2.3.1 Favorable federal funding for advanced BPH products to fuel market
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Increasing healthcare expenditure to drive market
    • 10.3.3 UK
      • 10.3.3.1 Availability of innovative treatment options for UTIs to drive market
    • 10.3.4 FRANCE
      • 10.3.4.1 Favorable private & public healthcare investments to fuel market
    • 10.3.5 ITALY
      • 10.3.5.1 Rising geriatric population and subsequent rise in obesity to propel market
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing uptake of UroLift procedures to drive market
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 JAPAN
      • 10.4.2.1 Mandatory health insurance programs to fuel uptake
    • 10.4.3 CHINA
      • 10.4.3.1 Rising demand for diagnostic procedures to drive market
    • 10.4.4 INDIA
      • 10.4.4.1 Expanding target patient population to drive market
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 High prevalence of obesity to support market growth
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Rising incidence of cancer to support market growth
    • 10.5.3 MEXICO
      • 10.5.3.1 Popularity in medical tourism to drive market
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 DEMAND FOR ADVANCED HEALTHCARE DIAGNOSTICS TO FUEL UPTAKE
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    • 10.7.1 RISING HEALTHCARE BUDGETS AND GROWING AWARENESS OF BPH TO SUPPORT MARKET GROWTH
    • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BPH SURGICAL TREATMENT MARKET
  • 11.3 REVENUE ANALYSIS, 2021-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX, BY DRUG TYPE: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
  • 11.6 COMPANY EVALUATION MATRIX, BY TYPE: KEY PLAYERS, 2023
    • 11.6.1 STARS
    • 11.6.2 EMERGING LEADERS
    • 11.6.3 PERVASIVE PLAYERS
    • 11.6.4 PARTICIPANTS
    • 11.6.5 COMPANY FOOTPRINT: KEY PLAYERS (DRUG TYPE AND TYPE), 2023
      • 11.6.5.1 Company footprint
      • 11.6.5.2 Region footprint
      • 11.6.5.3 Drug type footprint
      • 11.6.5.4 Type footprint
      • 11.6.5.5 End-user footprint
  • 11.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.7.1 PROGRESSIVE COMPANIES
    • 11.7.2 RESPONSIVE COMPANIES
    • 11.7.3 DYNAMIC COMPANIES
    • 11.7.4 STARTING BLOCKS
    • 11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
      • 11.7.5.1 Detailed list of key startups/SMEs
      • 11.7.5.2 Competitive benchmarking of key startups
  • 11.8 COMPANY VALUATION & FINANCIAL METRICS
  • 11.9 BRAND/PRODUCT COMPARISON
  • 11.10 COMPETITIVE SCENARIO
    • 11.10.1 PRODUCT LAUNCHES & APPROVALS
    • 11.10.2 DEALS
    • 11.10.3 EXPANSIONS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 GLAXOSMITHKLINE PLC
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses & competitive threats
    • 12.1.2 ELI LILLY AND COMPANY
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses & competitive threats
    • 12.1.3 TELEFLEX INCORPORATED
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product launches & approvals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 BOSTON SCIENTIFIC CORPORATION
      • 12.1.4.1 Business overview
      • 12.1.4.2 Recent developments
        • 12.1.4.2.1 Deals
        • 12.1.4.2.2 Expansions
      • 12.1.4.3 MnM view
        • 12.1.4.3.1 Key strengths
        • 12.1.4.3.2 Strategic choices
        • 12.1.4.3.3 Weaknesses & competitive threats
    • 12.1.5 PROCEPT BIOROBOTICS CORPORATION
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product approvals
        • 12.1.5.3.2 Expansions
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses & competitive threats
    • 12.1.6 ASTELLAS PHARMA INC.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
    • 12.1.7 ALEMBIC PHARMACEUTICALS LIMITED
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
    • 12.1.8 ASAHI KASEI CORPORATION
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
    • 12.1.9 ORGANON & CO.
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Deals
    • 12.1.10 OLYMPUS CORPORATION
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Deals
    • 12.1.11 COLOPLAST GROUP
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
    • 12.1.12 IPG PHOTONICS CORPORATION
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
    • 12.1.13 VIATRIS INC.
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products offered
    • 12.1.14 ABBVIE INC.
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products offered
      • 12.1.14.3 Recent developments
        • 12.1.14.3.1 Deals
    • 12.1.15 PROSTALUND AB
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 KARL STORZ SE & CO. KG
    • 12.2.2 RICHARD WOLF GMBH
    • 12.2.3 UNILAB, INC.
    • 12.2.4 BIOLITEC HOLDING GMBH & CO KG
    • 12.2.5 UROLOGIX, LLC.
    • 12.2.6 ADVIN HEALTH CARE
    • 12.2.7 MEDIFOCUS, INC.
    • 12.2.8 JENASURGICAL (ASCLEPION LASER TECHNOLOGIES GMBH)
    • 12.2.9 PNN MEDICAL A/S
    • 12.2.10 SURGICAL LASERS INC.
    • 12.2.11 QUANTA SYSTEM
    • 12.2.12 ALLIUM LTD.
    • 12.2.13 SRS MEDICAL
    • 12.2.14 LABORIE MEDICAL TECHNOLOGIES
    • 12.2.15 COOK MEDICAL

13 APPENDIX

  • 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.2 CUSTOMIZATION OPTIONS
  • 13.3 RELATED REPORTS
  • 13.4 AUTHOR DETAILS
Show more
Product Code: MD 7836

List of Tables

  • TABLE 1 BPH SURGICAL TREATMENT MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 2 ASSOCIATED SIDE EFFECTS OF BPH DRUGS
  • TABLE 3 PRODUCT RECALLS IN BPH TREATMENT MARKET
  • TABLE 4 BPH SURGICAL TREATMENT MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 5 BPH SURGICAL TREATMENT MARKET: PORTER'S FIVE FORCES FACTOR ANALYSIS
  • TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • TABLE 7 KEY BUYING CRITERIA (RANKING) FOR BPH SURGICAL TREATMENT MARKET, BY END USER
  • TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 AVERAGE SELLING PRICE TREND FOR UROLIFT, BY REGION, 2021-2023
  • TABLE 19 AVERAGE SELLING PRICE TREND OF DUTASTERIDE (AVODART), BY REGION, 2021-2023
  • TABLE 20 AVERAGE SELLING PRICING TREND FOR BPH SURGICAL TREATMENT PROCEDURES, 2021-2023
  • TABLE 21 IMPORT DATA FOR ENDOSCOPES (VALUE) BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 22 EXPORT DATA FOR ENDOSCOPES (VALUE) BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 23 IMPORT DATA FOR TADALAFIL (VALUE) BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 24 EXPORT DATA FOR TADALAFIL (VALUE) BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 25 BPH SURGICAL TREATMENT MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 26 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 27 BPH DRUG TYPE MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 28 NORTH AMERICA: BPH DRUG TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 29 EUROPE: BPH DRUG TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: BPH DRUG TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 31 LATIN AMERICA: BPH DRUG TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 32 ALPHA-BLOCKERS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 33 ALPHA-BLOCKERS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 35 EUROPE: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 38 ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 39 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 40 EUROPE: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 42 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 43 ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 44 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 45 EUROPE: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 47 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 48 ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 49 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 EUROPE: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 52 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 53 ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 54 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 55 EUROPE: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 57 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 58 OTHER ALPHA-BLOCKERS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 59 NORTH AMERICA: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 60 EUROPE: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 62 LATIN AMERICA: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 63 5-ALPHA REDUCTASE INHIBITORS MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 64 5-ALPHA REDUCTASE INHIBITORS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 66 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 68 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 69 5-ALPHA REDUCTASE INHIBITORS FOR DUTASTERIDE MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 71 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 73 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 74 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 75 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 76 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 78 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 79 OTHER DRUG TYPES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 80 NORTH AMERICA: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 81 EUROPE: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 83 LATIN AMERICA: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 84 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 85 BPH TYPE MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: BPH TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 EUROPE: BPH TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: BPH TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: BPH TYPE MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 90 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 91 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 92 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 94 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 95 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 97 EUROPE: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 100 BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 102 EUROPE: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 105 BPH SURGICAL TREATMENT MARKET FOR REZ?M PROCEDURES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 106 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR REZ?M PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 107 EUROPE: BPH SURGICAL TREATMENT MARKET FOR REZ?M PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR REZ?M PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 109 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR REZ?M PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 110 BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 112 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 114 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 115 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 117 EUROPE: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 119 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 120 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 122 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 124 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 125 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 126 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 127 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 129 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 130 BPH SURGICAL TREATMENT MARKET FOR PAE, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 131 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 132 EUROPE: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 134 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 135 BPH SURGICAL TREATMENT MARKET FOR OTHER PROCEDURES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 136 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 137 EUROPE: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 139 LATIN AMERICA: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 140 BPH THERAPY MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 141 BPH THERAPY MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: BPH THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 143 EUROPE: BPH THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: BPH THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: BPH THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 146 MONOTHERAPY MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 147 NORTH AMERICA: MONOTHERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 148 EUROPE: MONOTHERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: MONOTHERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 150 LATIN AMERICA: MONOTHERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 151 COMBINATION DRUG THERAPY MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 152 NORTH AMERICA: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 153 EUROPE: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 155 LATIN AMERICA: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 156 BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 157 BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 158 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 159 EUROPE: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 161 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 162 BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 163 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 164 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 166 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 167 BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 168 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 169 EUROPE: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 170 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 171 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 172 BPH SURGICAL TREATMENT MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 173 GLOBAL: ROBOT-ASSISTED WATERJET ABLATION SYSTEMS SOLD, 2022-2030 (MILLION UNITS)
  • TABLE 174 NORTH AMERICA: MACROINDICATORS
  • TABLE 175 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 176 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 177 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 178 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 179 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 180 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 181 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 182 US: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 183 US: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 184 US: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 185 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 186 US: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 187 US: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 188 CANADA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 189 CANADA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 190 CANADA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 191 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 192 CANADA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 193 CANADA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 194 EUROPE: MACROINDICATORS
  • TABLE 195 EUROPE: BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 196 EUROPE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 197 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 198 EUROPE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 199 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 200 EUROPE: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 201 EUROPE: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 202 GERMANY: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 203 GERMANY: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 204 GERMANY: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 205 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 206 GERMANY: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 207 GERMANY: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 208 UK: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 209 UK: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 210 UK: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 211 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 212 UK: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 213 UK: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 214 FRANCE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 215 FRANCE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 216 FRANCE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 217 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 218 FRANCE: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 219 FRANCE: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 220 ITALY: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 221 ITALY: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 222 ITALY: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 223 ITALY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 224 ITALY: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 225 ITALY: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 226 SPAIN: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 227 SPAIN: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 228 SPAIN: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 229 SPAIN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 230 SPAIN: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 231 SPAIN: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 232 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 233 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 234 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 235 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 236 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 237 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 238 ASIA PACIFIC: MACROINDICATORS
  • TABLE 239 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 242 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 243 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 244 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 245 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 246 JAPAN: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 247 JAPAN: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 248 JAPAN: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 249 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 250 JAPAN: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 251 JAPAN: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 252 CHINA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 253 CHINA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 254 CHINA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 255 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 256 CHINA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 257 CHINA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 258 INDIA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 259 INDIA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 260 INDIA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 261 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 262 INDIA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 263 INDIA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 264 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 265 AUSTRALIA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 266 AUSTRALIA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 267 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 268 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 269 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 270 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 271 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 272 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 276 LATIN AMERICA: MACROINDICATORS
  • TABLE 277 LATIN AMERICA BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 278 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 279 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 280 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 281 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 282 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 283 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 284 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 285 BRAZIL: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 286 BRAZIL: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 287 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 288 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 289 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 290 MEXICO: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 291 MEXICO: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 292 MEXICO: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 293 MEXICO: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 294 MEXICO: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 295 MEXICO: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 296 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 297 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 298 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 299 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 300 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 301 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 302 MIDDLE EAST & AFRICA: MACROINDICATORS
  • TABLE 303 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 304 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 305 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 306 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 307 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 308 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 309 GCC COUNTRIES: MACROINDICATORS
  • TABLE 310 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022-2030 (USD MILLION)
  • TABLE 311 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 312 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 313 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 314 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022-2030 (USD MILLION)
  • TABLE 315 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 316 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS
  • TABLE 317 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE: DEGREE OF COMPETITION
  • TABLE 318 BPH SURGICAL TREATMENT MARKET, BY TYPE: DEGREE OF COMPETITION
  • TABLE 319 BPH SURGICAL TREATMENT MARKET: COMPANY FOOTPRINT
  • TABLE 320 BPH SURGICAL TREATMENT MARKET: REGION FOOTPRINT
  • TABLE 321 BPH SURGICAL TREATMENT MARKET: DRUG TYPE FOOTPRINT
  • TABLE 322 BPH SURGICAL TREATMENT MARKET: TYPE FOOTPRINT
  • TABLE 323 BPH SURGICAL TREATMENT MARKET: END-USER FOOTPRINT
  • TABLE 324 BPH SURGICAL TREATMENT MARKET: DETAILED LIST OF KEY SME PLAYERS
  • TABLE 325 BPH SURGICAL TREATMENT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS
  • TABLE 326 BPH SURGICAL TREATMENT MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JANUARY 2025
  • TABLE 327 BPH SURGICAL TREATMENT MARKET: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 328 BPH SURGICAL TREATMENT MARKET: EXPANSIONS, JANUARY 2021-JANUARY 2025
  • TABLE 329 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
  • TABLE 330 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
  • TABLE 331 GLAXOSMITHKLINE PLC: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 332 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 333 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 334 ELI LILLY AND COMPANY: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 335 TELEFLEX INCORPORATED: COMPANY OVERVIEW
  • TABLE 336 TELEFLEX INCORPORATED: PRODUCTS OFFERED
  • TABLE 337 TELEFLEX INCORPORATED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JANUARY 2025
  • TABLE 338 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 339 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 340 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 341 BOSTON SCIENTIFIC CORPORATION: EXPANSIONS, JANUARY 2021-JANUARY 2025
  • TABLE 342 PROCEPT BIOROBOTICS CORPORATION: COMPANY OVERVIEW
  • TABLE 343 PROCEPT BIOROBOTICS CORPORATION: PRODUCTS OFFERED
  • TABLE 344 PROCEPT BIOROBOTICS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JANUARY 2025
  • TABLE 345 PROCEPT BIOROBOTICS CORPORATION: EXPANSIONS, JANUARY 2021-JANUARY 2025
  • TABLE 346 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
  • TABLE 347 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
  • TABLE 348 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
  • TABLE 349 ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
  • TABLE 350 ASAHI KASEI CORPORATION: COMPANY OVERVIEW
  • TABLE 351 ASAHI KASEI CORPORATION: PRODUCTS OFFERED
  • TABLE 352 ORGANON & CO.: COMPANY OVERVIEW
  • TABLE 353 ORGANON & CO.: PRODUCTS OFFERED
  • TABLE 354 ORGANON & CO.: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 355 OLYMPUS CORPORATION: COMPANY OVERVIEW
  • TABLE 356 OLYMPUS CORPORATION: PRODUCTS OFFERED
  • TABLE 357 OLYMPUS CORPORATION: DEALS, JANUARY 2021-JANUARY 2021
  • TABLE 358 COLOPLAST GROUP: COMPANY OVERVIEW
  • TABLE 359 COLOPLAST GROUP: PRODUCTS OFFERED
  • TABLE 360 IPG PHOTONICS CORPORATION: COMPANY OVERVIEW
  • TABLE 361 IPG PHOTONICS CORPORATION: PRODUCTS OFFERED
  • TABLE 362 VIATRIS INC.: COMPANY OVERVIEW
  • TABLE 363 VIATRIS INC.: PRODUCTS OFFERED
  • TABLE 364 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 365 ABBVIE INC.: PRODUCTS OFFERED
  • TABLE 366 ABBVIE INC.: DEALS, JANUARY 2021-JANUARY 2025
  • TABLE 367 PROSTALUND AB: COMPANY OVERVIEW
  • TABLE 368 PROSTALUND AB: PRODUCTS OFFERED

List of Figures

  • FIGURE 1 MARKETS & REGIONS COVERED
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 BPH SURGICAL TREATMENT MARKET: REVENUE ESTIMATION APPROACH, BY TYPE
  • FIGURE 6 BPH SURGICAL TREATMENT MARKET: REVENUE ESTIMATION APPROACH, BY DRUG TYPE
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 BPH SURGICAL TREATMENT MARKET: TOP-DOWN APPROACH
  • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 11 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 12 BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2024 VS. 2030 (USD MILLION)
  • FIGURE 13 BPH SURGICAL TREATMENT, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 14 GEOGRAPHIC SNAPSHOT OF BPH SURGICAL TREATMENT MARKET
  • FIGURE 15 EXPANDING GERIATRIC POPULATION AND INCREASING PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA TO PROPEL MARKET
  • FIGURE 16 ALPHA-BLOCKERS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN US IN 2023
  • FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 18 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 19 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20 BHP SURGICAL TREATMENT MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES
  • FIGURE 21 BPH SURGICAL TREATMENT MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 22 BPH SURGICAL TREATMENT MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 23 KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET ECOSYSTEM
  • FIGURE 24 BPH SURGICAL TREATMENT MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BPH SURGICAL TREATMENT MARKET
  • FIGURE 26 KEY BUYING CRITERIA FOR BPH SURGICAL TREATMENT, BY END USER
  • FIGURE 27 BPH SURGICAL TREATMENT MARKET: PESTLE ANALYSIS
  • FIGURE 28 PATENT ANALYSIS FOR PROSTATIC STENTS: JANUARY 2015-DECEMBER 2024
  • FIGURE 29 PATENT ANALYSIS FOR TRANSURETHRAL CATHETERS: JANUARY 2015-DECEMBER 2024
  • FIGURE 30 PATENT ANALYSIS FOR AVODART: JANUARY 2015-DECEMBER 2024
  • FIGURE 31 PATENT ANALYSIS FOR ALFUZOSIN: JANUARY 2015-DECEMBER 2024
  • FIGURE 32 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESSES IN BPH SURGICAL TREATMENT MARKET
  • FIGURE 33 BPH SURGICAL TREATMENT MARKET: NUMBER OF DEALS & VENTURES
  • FIGURE 34 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET SNAPSHOT
  • FIGURE 35 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET SNAPSHOT
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT, 2021-2023
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE (2023)
  • FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET, BY TYPE (2023)
  • FIGURE 39 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR DRUG TYPE (KEY PLAYERS), 2023
  • FIGURE 40 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR TYPE, (KEY PLAYERS), 2023
  • FIGURE 41 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 42 EV/EBITDA OF KEY VENDORS, 2023-2024
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 44 BPH SURGICAL TREATMENT MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 45 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 47 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023)
  • FIGURE 48 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 49 PROCEPT BIOROBOTICS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 50 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 51 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023)
  • FIGURE 52 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 53 ORGANON & CO.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 COLOPLAST GROUP: COMPANY SNAPSHOT (2024)
  • FIGURE 56 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 57 VIATRIS INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 58 ABBVIE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 PROSTALUND AB: COMPANY SNAPSHOT (2023)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!